In recent trading session, Zomedica Corp. (AMEX:ZOM) saw 3.18 million shares changing hands at last check today with its beta currently measuring 0.98. Company’s recent per share price level of $0.16 trading at -$0.01 or -4.82% at last check today assigns it a market valuation of $159.49M. That most recent trading price of ZOM’s stock is at a discount of -112.5% from its 52-week high price of $0.34 and is indicating a premium of 6.25% from its 52-week low price of $0.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.1 million shares which gives us an average trading volume of 4.13 million if we extend that period to 3-months.
For Zomedica Corp. (ZOM), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Zomedica Corp. (AMEX:ZOM) trade information
Upright in the red during last session for losing -4.82%, in the last five days ZOM remained trading in the red while hitting it’s week-highest on Monday, 09/11/23 when the stock touched $0.16 price level, adding 12.09% to its value on the day. Zomedica Corp.’s shares saw a change of -0.55% in year-to-date performance and have moved -10.09% in past 5-day. Zomedica Corp. (AMEX:ZOM) showed a performance of -16.87% in past 30-days. Number of shares sold short was 68.63 million shares which calculate 16.24 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $0.44 to the stock, which implies a rise of 63.64% to its recent value today. Analysts have been projecting $0.44 as a low price target for the stock while placing it at a high target of $0.44. It follows that stock’s current price would drop -175.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -175.0% for stock’s current value.
Zomedica Corp. (ZOM) estimates and forecasts
Statistics highlight that Zomedica Corp. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -30.31% of value to its shares in past 6 months, showing an annual growth rate of 50.00% while that of industry is 19.10. Apart from that, the company came raising its revenue forecast for fiscal year 2023. This year revenue growth is estimated to rise 61.60% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $8.28 million for the same. And 1 analysts are in estimates of company making revenue of $10.81 million in the next quarter that will end on Dec 2023.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 28.40% during past 5 years.
Zomedica Corp. is more likely to be releasing its next quarterly report on November 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Zomedica Corp. (AMEX:ZOM)’s Major holders
Insiders are in possession of 1.42% of company’s total shares while institution are holding 9.74 percent of that, with stock having share float percentage of 9.88%. Investors also watch the number of corporate investors in a company very closely, which is 9.74% institutions for Zomedica Corp. that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at ZOM for having 48.81 million shares of worth $7.92 million. And as of Jun 29, 2023, it was holding 4.98% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 11.51 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 1.17% of outstanding shares, having a total worth of $1.87 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 33.69 million shares of worth $5.47 million or 3.44% of the total outstanding shares. The later fund manager was in possession of 13.32 million shares on Jun 29, 2023, making its stake of worth around $2.16 million in the company or a holder of 1.36% of company’s stock.